WinnMed

BACKGROUND: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the American Thyroid Association's (ATA's) guidelines for the management of these disorders were revised in 2009, significant scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, researchers, and health policy makers on published evidence relating to the diagnosis and management of thyroid nodules and differentiated thyroid cancer. METHODS: The specific clinical questions addressed in these guidelines were based on prior versions of the guidelines, stakeholder input, and input of task force members. Task force panel members were educated on knowledge synthesis methods, including electronic database searching, review and selection of relevant citations, and critical appraisal of selected studies. Published English language articles on adults were eligible for inclusion. The American College of Physicians Guideline Grading System was used for critical appraisal of evidence and grading strength of recommendations for therapeutic interventions. We developed a similarly formatted system to appraise the quality of such studies and resultant recommendations. The guideline panel had complete editorial independence from the ATA. Competing interests of guideline task force members were regularly updated, managed, and communicated to the ATA and task force members. RESULTS: The revised guidelines for the management of thyroid nodules include recommendations regarding initial evaluation, clinical and ultrasound criteria for fine-needle aspiration biopsy, interpretation of fine-needle aspiration biopsy results, use of molecular markers, and management of benign thyroid nodules. Recommendations regarding the initial management of thyroid cancer include those relating to screening for thyroid cancer, staging and risk assessment, surgical management, radioiodine remnant ablation and therapy, and thyrotropin suppression therapy using levothyroxine. Recommendations related to long-term management of differentiated thyroid cancer include those related to surveillance for recurrent disease using imaging and serum thyroglobulin, thyroid hormone therapy, management of recurrent and metastatic disease, consideration for clinical trials and targeted therapy, as well as directions for future research. CONCLUSIONS: We have developed evidence-based recommendations to inform clinical decision-making in the management of thyroid nodules and differentiated thyroid cancer. They represent, in our opinion, contemporary optimal care for patients with these disorders.

Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of global mortality and a major contributor to disability. This paper reviews the magnitude of total CVD burden, including 13 underlying causes of cardiovascular death and 9 related risk factors, using estimates from the Global Burden of Disease (GBD) Study 2019. GBD, an ongoing multinational collaboration to provide comparable and consistent estimates of population health over time, used all available population-level data sources on incidence, prevalence, case fatality, mortality, and health risks to produce estimates for 204 countries and territories from 1990 to 2019. Prevalent cases of total CVD nearly doubled from 271 million (95% uncertainty interval [UI]: 257 to 285 million) in 1990 to 523 million (95% UI: 497 to 550 million) in 2019, and the number of CVD deaths steadily increased from 12.1 million (95% UI:11.4 to 12.6 million) in 1990, reaching 18.6 million (95% UI: 17.1 to 19.7 million) in 2019. The global trends for disability-adjusted life years (DALYs) and years of life lost also increased significantly, and years lived with disability doubled from 17.7 million (95% UI: 12.9 to 22.5 million) to 34.4 million (95% UI:24.9 to 43.6 million) over that period. The total number of DALYs due to IHD has risen steadily since 1990, reaching 182 million (95% UI: 170 to 194 million) DALYs, 9.14 million (95% UI: 8.40 to 9.74 million) deaths in the year 2019, and 197 million (95% UI: 178 to 220 million) prevalent cases of IHD in 2019. The total number of DALYs due to stroke has risen steadily since 1990, reaching 143 million (95% UI: 133 to 153 million) DALYs, 6.55 million (95% UI: 6.00 to 7.02 million) deaths in the year 2019, and 101 million (95% UI: 93.2 to 111 million) prevalent cases of stroke in 2019. Cardiovascular diseases remain the leading cause of disease burden in the world. CVD burden continues its decades-long rise for almost all countries outside high-income countries, and alarmingly, the age-standardized rate of CVD has begun to rise in some locations where it was previously declining in high-income countries. There is an urgent need to focus on implementing existing cost-effective policies and interventions if the world is to meet the targets for Sustainable Development Goal 3 and achieve a 30% reduction in premature mortality due to noncommunicable diseases.

OBJECTIVE: The objective was to provide guidelines to clinicians for the evaluation, treatment, and prevention of vitamin D deficiency with an emphasis on the care of patients who are at risk for deficiency. PARTICIPANTS: The Task Force was composed of a Chair, six additional experts, and a methodologist. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions during several conference calls and e-mail communications. The draft prepared by the Task Force was reviewed successively by The Endocrine Society's Clinical Guidelines Subcommittee, Clinical Affairs Core Committee, and cosponsoring associations, and it was posted on The Endocrine Society web site for member review. At each stage of review, the Task Force received written comments and incorporated needed changes. CONCLUSIONS: Considering that vitamin D deficiency is very common in all age groups and that few foods contain vitamin D, the Task Force recommended supplementation at suggested daily intake and tolerable upper limit levels, depending on age and clinical circumstances. The Task Force also suggested the measurement of serum 25-hydroxyvitamin D level by a reliable assay as the initial diagnostic test in patients at risk for deficiency. Treatment with either vitamin D(2) or vitamin D(3) was recommended for deficient patients. At the present time, there is not sufficient evidence to recommend screening individuals who are not at risk for deficiency or to prescribe vitamin D to attain the noncalcemic benefit for cardiovascular protection.

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.

A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients’ lives. The Cancer Genome Atlas project has analysed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours. Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1, BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes. Analyses delineated four ovarian cancer transcriptional subtypes, three microRNA subtypes, four promoter methylation subtypes and a transcriptional signature associated with survival duration, and shed new light on the impact that tumours with BRCA1/2 (BRCA1 or BRCA2) and CCNE1 aberrations have on survival. Pathway analyses suggested that homologous recombination is defective in about half of the tumours analysed, and that NOTCH and FOXM1 signalling are involved in serous ovarian cancer pathophysiology. The Cancer Genome Atlas (TCGA) project reports here its analysis of messenger RNA and microRNA expression, promoter methylation, DNA copy number and exome sequences in 489 high-grade serous ovarian adenocarcinomas. The analyses help establish new tumour subtypes. Among other insights is the finding that while the gene encoding p53 tumour suppressor is mutated in almost all tumours, nine other loci including NF1, BRCA1, BRCA2, RB1 and CDK12 carry recurrent albeit low-prevalence mutations. Homologous recombination is defective in about half of the tumours studied, and Notch and FOXM1 signalling are involved in the pathophysiology.

BACKGROUND: The Global Burden of Diseases, Injuries, and Risk Factors Study 2015 provides an up-to-date synthesis of the evidence for risk factor exposure and the attributable burden of disease. By providing national and subnational assessments spanning the past 25 years, this study can inform debates on the importance of addressing risks in context. METHODS: We used the comparative risk assessment framework developed for previous iterations of the Global Burden of Disease Study to estimate attributable deaths, disability-adjusted life-years (DALYs), and trends in exposure by age group, sex, year, and geography for 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks from 1990 to 2015. This study included 388 risk-outcome pairs that met World Cancer Research Fund-defined criteria for convincing or probable evidence. We extracted relative risk and exposure estimates from randomised controlled trials, cohorts, pooled cohorts, household surveys, census data, satellite data, and other sources. We used statistical models to pool data, adjust for bias, and incorporate covariates. We developed a metric that allows comparisons of exposure across risk factors-the summary exposure value. Using the counterfactual scenario of theoretical minimum risk level, we estimated the portion of deaths and DALYs that could be attributed to a given risk. We decomposed trends in attributable burden into contributions from population growth, population age structure, risk exposure, and risk-deleted cause-specific DALY rates. We characterised risk exposure in relation to a Socio-demographic Index (SDI). FINDINGS: Between 1990 and 2015, global exposure to unsafe sanitation, household air pollution, childhood underweight, childhood stunting, and smoking each decreased by more than 25%. Global exposure for several occupational risks, high body-mass index (BMI), and drug use increased by more than 25% over the same period. All risks jointly evaluated in 2015 accounted for 57·8% (95% CI 56·6-58·8) of global deaths and 41·2% (39·8-42·8) of DALYs. In 2015, the ten largest contributors to global DALYs among Level 3 risks were high systolic blood pressure (211·8 million [192·7 million to 231·1 million] global DALYs), smoking (148·6 million [134·2 million to 163·1 million]), high fasting plasma glucose (143·1 million [125·1 million to 163·5 million]), high BMI (120·1 million [83·8 million to 158·4 million]), childhood undernutrition (113·3 million [103·9 million to 123·4 million]), ambient particulate matter (103·1 million [90·8 million to 115·1 million]), high total cholesterol (88·7 million [74·6 million to 105·7 million]), household air pollution (85·6 million [66·7 million to 106·1 million]), alcohol use (85·0 million [77·2 million to 93·0 million]), and diets high in sodium (83·0 million [49·3 million to 127·5 million]). From 1990 to 2015, attributable DALYs declined for micronutrient deficiencies, childhood undernutrition, unsafe sanitation and water, and household air pollution; reductions in risk-deleted DALY rates rather than reductions in exposure drove these declines. Rising exposure contributed to notable increases in attributable DALYs from high BMI, high fasting plasma glucose, occupational carcinogens, and drug use. Environmental risks and childhood undernutrition declined steadily with SDI; low physical activity, high BMI, and high fasting plasma glucose increased with SDI. In 119 countries, metabolic risks, such as high BMI and fasting plasma glucose, contributed the most attributable DALYs in 2015. Regionally, smoking still ranked among the leading five risk factors for attributable DALYs in 109 countries; childhood underweight and unsafe sex remained primary drivers of early death and disability in much of sub-Saharan Africa. INTERPRETATION: Declines in some key environmental risks have contributed to declines in critical infectious diseases. Some risks appear to be invariant to SDI. Increasing risks, including high BMI, high fasting plasma glucose, drug use, and some occupational exposures, contribute to rising burden from some conditions, but also provide opportunities for intervention. Some highly preventable risks, such as smoking, remain major causes of attributable DALYs, even as exposure is declining. Public policy makers need to pay attention to the risks that are increasingly major contributors to global burden. FUNDING: Bill & Melinda Gates Foundation.

This document is an international evidence-based guideline on the diagnosis and management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association. It represents the current state of knowledge regarding idiopathic pulmonary fibrosis (IPF), and contains sections on definition and epidemiology, risk factors, diagnosis, natural history, staging and prognosis, treatment, and monitoring disease course. For the diagnosis and treatment sections, pragmatic GRADE evidence-based methodology was applied in a question-based format. For each diagnosis and treatment question, the committee graded the quality of the evidence available (high, moderate, low, or very low), and made a recommendation (yes or no, strong or weak). Recommendations were based on majority vote. It is emphasized that clinicians must spend adequate time with patients to discuss patients' values and preferences and decide on the appropriate course of action.

The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long "preclinical" phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from "normal" cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease-modifying therapies may be most efficacious.

BACKGROUND AND OBJECTIVE: The Atlanta classification of acute pancreatitis enabled standardised reporting of research and aided communication between clinicians. Deficiencies identified and improved understanding of the disease make a revision necessary. METHODS: A web-based consultation was undertaken in 2007 to ensure wide participation of pancreatologists. After an initial meeting, the Working Group sent a draft document to 11 national and international pancreatic associations. This working draft was forwarded to all members. Revisions were made in response to comments, and the web-based consultation was repeated three times. The final consensus was reviewed, and only statements based on published evidence were retained. RESULTS: The revised classification of acute pancreatitis identified two phases of the disease: early and late. Severity is classified as mild, moderate or severe. Mild acute pancreatitis, the most common form, has no organ failure, local or systemic complications and usually resolves in the first week. Moderately severe acute pancreatitis is defined by the presence of transient organ failure, local complications or exacerbation of co-morbid disease. Severe acute pancreatitis is defined by persistent organ failure, that is, organ failure >48 h. Local complications are peripancreatic fluid collections, pancreatic and peripancreatic necrosis (sterile or infected), pseudocyst and walled-off necrosis (sterile or infected). We present a standardised template for reporting CT images. CONCLUSIONS: This international, web-based consensus provides clear definitions to classify acute pancreatitis using easily identified clinical and radiologic criteria. The wide consultation among pancreatologists to reach this consensus should encourage widespread adoption.

The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity of chronic graft-versus-host disease (GVHD). The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence. Revisions have been made to address areas of controversy or confusion, such as the overlap chronic GVHD subcategory and the distinction between active disease and past tissue damage. Diagnostic criteria for involvement of mouth, eyes, genitalia, and lungs have been revised. Categories of chronic GVHD should be defined in ways that indicate prognosis, guide treatment, and define eligibility for clinical trials. Revisions have been made to focus attention on the causes of organ-specific abnormalities. Attribution of organ-specific abnormalities to chronic GVHD has been addressed. This paradigm shift provides greater specificity and more accurately measures the global burden of disease attributed to GVHD, and it will facilitate biomarker association studies.

The dementia with Lewy bodies (DLB) Consortium has revised criteria for the clinical and pathologic diagnosis of DLB incorporating new information about the core clinical features and suggesting improved methods to assess them. REM sleep behavior disorder, severe neuroleptic sensitivity, and reduced striatal dopamine transporter activity on functional neuroimaging are given greater diagnostic weighting as features suggestive of a DLB diagnosis. The 1-year rule distinguishing between DLB and Parkinson disease with dementia may be difficult to apply in clinical settings and in such cases the term most appropriate to each individual patient should be used. Generic terms such as Lewy body (LB) disease are often helpful. The authors propose a new scheme for the pathologic assessment of LBs and Lewy neurites (LN) using alpha-synuclein immunohistochemistry and semiquantitative grading of lesion density, with the pattern of regional involvement being more important than total LB count. The new criteria take into account both Lewy-related and Alzheimer disease (AD)-type pathology to allocate a probability that these are associated with the clinical DLB syndrome. Finally, the authors suggest patient management guidelines including the need for accurate diagnosis, a target symptom approach, and use of appropriate outcome measures. There is limited evidence about specific interventions but available data suggest only a partial response of motor symptoms to levodopa: severe sensitivity to typical and atypical antipsychotics in approximately 50%, and improvements in attention, visual hallucinations, and sleep disorders with cholinesterase inhibitors.

Impaired Autophagic-Lysosomal Fusion in Parkinson's Patient Midbrain Neurons Occurs through Loss of ykt6 and Is Rescued by Farnesyltransferase Inhibition,

Potential conflict of interest: Laura M. Kulik is on the advisory board for Gilead, Bayer, Eisai, Salix, and Bristol‐Myers Squibb. Richard Finn consults for Pfizer, Bayer, Novartis, Merck, and Bristol‐Myers Squibb. Claude B. Sirlin consults for and has received grants from Virtualscopics. Lewis R. Roberts consults for Wako, Medscape, and Axis; advises Tavec and Bayer; is on the speakers' bureau for Onlive; and has received grants from Ariad, BTG, and Gilead. Andrew Zhu consults for Bristol‐Myers Squibb, Eisai, Merck, Novartis, Sanofi, and Bayer. The funding for the development of this Practice Guideline was provided by the American Association for the Study of Liver Diseases. Guiding Principles and Objectives GUIDING PRINCIPLES This document presents official recommendations of the American Association for the Study of Liver Diseases (AASLD) on the surveillance, diagnosis, and treatment of hepatocellular carcinoma (HCC) occurring in the setting of adults with cirrhosis. Unlike previous AASLD practice guidelines, the current guideline was developed in compliance with the Institute of Medicine standards for trustworthy practice guidelines and uses the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach.1 Multiple systematic reviews of the literature were conducted to support the recommendations in this practice guideline. An enhanced understanding of the guideline can be obtained by reading the applicable portions of the systematic reviews. In addition, more detailed information may be found in the associated guidance document related to clinically important aspects of HCC that lacked sufficient evidence to warrant a systematic review. The guideline focuses on a broad spectrum of clinical practice, including surveillance of patients with cirrhosis for HCC, establishing the diagnosis of HCC, and various therapeutic options for the treatment of HCC. To address other issues on HCC such as epidemiology, staging, and additional aspects of diagnosis and treatment, the authors have created a new guidance document that will be published soon and is based upon the previous HCC AASLD guidelines by Bruix and Sherman.2 KEY QUESTIONS The guideline developers from the AASLD identified key questions that health care providers are faced with frequently in the evaluation and management of patients with HCC. These questions were: Should adults with cirrhosis undergo surveillance for HCC? If so, which surveillance test is best? Should adults with cirrhosis and suspected HCC undergo diagnostic evaluation with multiphasic computed tomography (CT) or multiphasic magnetic resonance imaging (MRI)? Should adults with cirrhosis and an indeterminate hepatic nodule undergo a biopsy, repeated imaging, or alternative imaging for the diagnostic evaluation? Should adults with Child‐Pugh class A cirrhosis and early‐stage HCC (T1 or T2) be treated with resection or local‐regional (LRT) therapy? Should adults with cirrhosis and HCC that has been resected or ablated successfully undergo adjuvant therapy? Should adults with cirrhosis awaiting liver transplantation and HCC (T1) be treated or undergo observation? Should adults with cirrhosis and HCC (Organ Procurement and Transplantation Network [OPTN] T2) awaiting liver transplantation undergo transplantation alone or transplantation with bridging therapy while waiting? Should adults with cirrhosis awaiting liver transplantation and HCC beyond Milan criteria (T3) undergo transplantation after being down‐staged to within Milan criteria? Should adults with cirrhosis and HCC (T2 or T3, no vascular involvement) who are not candidates for resection or transplantation be treated with transarterial chemoembolization, transarterial radioembolization, or external radiation? Should adults with Child‐Pugh class A/B cirrhosis and advanced HCC with macrovascular invasion and/or metastatic disease be treated with systemic or locoregional therapies or no therapy? TARGET AUDIENCE This guideline is intended primarily for health care providers who care for patients with cirrhosis. Additionally, the guideline may inform policy decisions regarding patients with HCC. Background BURDEN OF DISEASE According to the World Health Organization, HCC is the fifth most common tumor worldwide and the second most common cause of cancer‐related death (http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp). Male‐to‐female predominance is greater than 2:1 with liver cancer, and approximately 83% of the estimated 782,000 new HCC cases in 2012 occurred in less developed regions of the world, with East and South Asia plus sub‐Saharan Africa being the regions of highest incidence, Southern Europe and North America being the regions of intermediate incidence, and Northern Europe and South Central Asia being the regions of lowest incidence.3 The incidence of HCC has been rising rapidly in the United States over the last 20 years.4 According to estimates from the Surveillance Epidemiology End Results (SEER) program of the National Cancer Institute, the United States will have an estimated cases of HCC and HCC in In addition, a the that the incidence of HCC will to with the highest in by and with a The in incidence of HCC in the United States is primarily to the to that the with the highest of have that as liver disease and the more to the of HCC than other including which is primarily to the of in the The of cirrhosis a key for the development of HCC. The of cirrhosis patients with HCC has been estimated to be and the HCC incidence patients with cirrhosis has been to be patients with cirrhosis a for and The that patients with HCC have liver disease the management and therapeutic options The key questions common in this and the for this practice guideline. the Child‐Pugh to the of liver of the for Liver is more in this of Guideline Development An and the of the key A of AASLD with an in systematic reviews to the The provided evidence the In this the of evidence in systematic is as or based on the of and of a of systematic the guideline based recommendations on the of the of and and and other clinical on this the guideline AASLD recommendations that are as to most patients with or to a of The of is not by the of the of and and and of the a in the of are to recommendations to the of the with the of the evidence and to for the systematic for of the key questions are in the the key questions with are after The the of evidence Study of of evidence of the of the of a of evidence of and and and of the of a in this the of and a Health care the of The can be as policy in most The of in this the of Health care to patients a that is with and is a for and of a that most patients in this the of and a this that patients the of with and policy the be as a policy in most and be as a the is by AASLD a a for patients that the of patients in this the of a the of and is and be to patients a that is with a policy this a for and of and is to be as a the is by AASLD with cirrhosis Surveillance for HCC surveillance with cirrhosis and suspected HCC evaluation with multiphasic evaluation with multiphasic and with cirrhosis and an indeterminate hepatic nodule or alternative imaging and with Child‐Pugh class A cirrhosis and or HCC therapy with cirrhosis and HCC successfully resected or ablated therapy adjuvant therapy with cirrhosis awaiting liver transplantation and HCC therapy to with cirrhosis awaiting liver transplantation and HCC therapy to with cirrhosis awaiting liver transplantation and HCC and with cirrhosis and HCC (T2 or T3, no vascular involvement) who are not candidates for resection or transplantation or external with Child‐Pugh class A/B cirrhosis and advanced HCC with macrovascular invasion and/or metastatic disease therapy therapy or no therapy Should Surveillance for HCC, and If Surveillance The AASLD surveillance of adults with cirrhosis of of The AASLD surveillance with or of of The AASLD not surveillance of patients with Child‐Pugh class cirrhosis are on the the for of the of is not to which of surveillance alone or the of plus to a greater in The of surveillance from to in surveillance based on of liver or be this The of surveillance and is to HCC the criteria for the development of a surveillance that patients with cirrhosis are a and can be The previous AASLD guidelines on the the highest to have and cirrhosis to A surveillance in a in for who are no in with cirrhosis to or liver and is surveillance to a in in this of patients with cirrhosis. of is which surveillance be is that be of surveillance, is the of such as for The previous AASLD guidelines as the of the of this was to current are in support of HCC surveillance in adults with and so, of surveillance is and The evidence of surveillance for HCC is in which uses the from a systematic on were no of surveillance in patients with cirrhosis. were that surveillance in patients with the of the evidence The of the was with The was the patients who HCC surveillance, with the patients previous surveillance, with an of were that for and the in of for surveillance the were in which the with surveillance was greater than no surveillance In to surveillance to an in the of early‐stage HCC, with an of with no In of surveillance to more patients with no In addition, surveillance to more with no surveillance in with surveillance to be to early‐stage and treatment The surveillance most were and the the on and The of plus of early‐stage HCC with no surveillance, with an of alone an of alone and plus to of treatment for and for plus were no that alone plus to which was in of early‐stage or The were to alone or plus plus a of for alone a of for was no the are issues surveillance for on which no of the to a diagnostic to or than the no of the of and most the were not to an in the current of HCC and the in incidence of this including with plus as surveillance are the of including and as a surveillance test in In addition, be important to other in to such as and other Should and HCC Evaluation or Recommendation The AASLD diagnostic evaluation for HCC with multiphasic or multiphasic of diagnostic of for of The of the and for a on beyond diagnostic These and and were of the greater of multiphasic with multiphasic to liver is not In patients with cirrhosis and suspected HCC, diagnostic imaging is to the of HCC and The are to tumor and patients for liver Unlike most other the diagnosis of HCC can be and treatment may be based on imaging The is that in patients with the of HCC is and the of that may HCC imaging is such that a HCC imaging criteria can be and to be HCC. is that the imaging diagnosis of HCC multiphasic imaging, is not which diagnostic imaging test to in clinical practice multiphasic with multiphasic with that in the and of and multiphasic with that in and of hepatocellular in to The evidence of diagnostic for HCC is in which uses the from a systematic on imaging in HCC to address this were no of no identified that multiphasic with an multiphasic with and no on were in patients with cirrhosis and suspected HCC that the diagnostic of and and An additional are not as be in the of on and/or of evidence was and was of the of the and The of imaging and for of are to multiphasic an multiphasic with an provided than with multiphasic with multiphasic with provided than with than multiphasic with an multiphasic and a with a of in HCC and were that multiphasic and this and HCC multiphasic multiphasic with an The of for was with the a multiphasic may be more than in a of the in diagnostic are to over the of the to and that beyond diagnostic inform the of imaging in with multiphasic multiphasic has important and greater more of nodule and liver and of greater to less of such as or of the United and a is more and less patients to and the of which may be in patients with or not in North multiphasic can be to HCC and are multiphasic multiphasic with an and multiphasic with and on and be a of transplantation patients with HCC and while awaiting transplantation has and may which is in this Should and an a or for the The AASLD options in patients with cirrhosis and an indeterminate including imaging, imaging with an alternative or alternative or biopsy, over the of of The AASLD of indeterminate of of may be in is not has the to a diagnosis in cases in which a diagnosis is to therapeutic has a of tumor and the that a is to the to of the nodule than a imaging criteria with for HCC have been developed by the American of Liver and the and previous AASLD and in with and/or that not guidelines or are than are In previous HCC clinical practice the AASLD for indeterminate by surveillance with the being that can a diagnosis, of may not be an in is may cause or and has a of including tumor and for is an additional A may not and repeated may be to a imaging may be in patients awaiting liver transplantation with a indeterminate that of HCC not management or to liver transplantation is regarding for an indeterminate the of this was to current are to an The evidence is in which uses the from a systematic on imaging in HCC to address this on an detailed in the systematic were no identified that address this were identified that the of in for hepatic surveillance in patients with cirrhosis. The authors of in to and found a and of to be and was and with the which was were in the was with a of as patients with imaging or were to In that in patients with of to indeterminate surveillance are the of that for indeterminate hepatic may be and an alternative of imaging with imaging an for most indeterminate with for with or in the of a HCC. other of indeterminate as by or not most indeterminate hepatic are for are the of indeterminate or The indeterminate were as intermediate of HCC, and HCC based on imaging as to HCC of as intermediate to HCC, and of as HCC to HCC. in that the various are associated with of HCC in patients with as the that a of to indeterminate are and to to HCC imaging a of a of indeterminate in a of indeterminate diagnostic options imaging, imaging with an alternative or and to a A by and for a of patients with identified by surveillance The authors that and of the of the diagnostic was and and that be for on or An diagnostic based on clinical and imaging such as nodule of biopsy, and may be the In a may to a HCC and patients to be that such treatment may is to the of and the of nodule and to additional to more including other than such as or from the Should Child‐Pugh A and HCC (T1 T2) or Recommendation The AASLD that adults with Child‐Pugh class A cirrhosis and or HCC undergo resection over of of of resection other of as transarterial and transarterial or other of such as and not evidence The of is not or in clinical practice, and is not in is as from a in such as of and This to in and HCC a of tumor from to and the of therapies in on the and of the that are may be treated by resection or than or vascular or may have Multiple that are or may not be to to resection have been primarily in East in is a of and a of other liver such as or with The of on of therapies is cirrhosis is of the for HCC, the of treatment as on the liver and the of as on the of the therapeutic options are for patients who with advanced liver disease and/or advanced tumor options for with cirrhosis and These such as and as as patients with HCC as with to with an of for and for more than to evidence of disease or macrovascular and occurring in the setting of or no and in the of Liver Cancer or a of clinical and and including the of alternative can the to with The of a of a of the of from of resection to of and may to and In this be that the evidence was to resection with therapy to the therapeutic for patients with early‐stage HCC occurring in the setting of cirrhosis or no and that liver transplantation is for patients with HCC, not a of transplantation to resection or The evidence is in which the from a systematic by on treatment for early‐stage HCC in patients with Child‐Pugh class A or cirrhosis. This systematic not the of or other with or found evidence that In the resection and the other the authors of the systematic that the of patients was to a were that with including a of of a of and evidence and a of The of the that hepatic resection is more than regarding as as a with a of is to the the in resection and The for an of in the is related to an of patients who from the to the resection were within the of to the of The additional of and resection of of the the was for resection with In to the in the systematic by resection with published the of for patients after resection with with was by within and and for the resection resection with alone for to and Milan criteria to with the being and found resection to be in and of was a for in of the systematic review. This is not that is that is more in the of for patients with HCC treated with resection has not been in an A from this This Child‐Pugh class A patients from and the authors for for for for and for for A for of was not by the in the systematic that resection with in patients with This was not in the other The of other than such as and In addition, the of such as transarterial and have not been with resection or in Child‐Pugh class A patients with or HCC. Should and HCC or Recommendation The AASLD the of adjuvant therapy for patients with HCC resection or of of The Evaluation in may be the most common criteria to in patients by HCC and treated with other are The of after resection or is related to of the tumor the of such as of and the or of the of HCC in which of the tumor and the development of the adjuvant therapy have an the tumor and a the development of a The of is and based on the of the with the to be related to the development of a with the adjuvant of were with a in the development of not a The of in advanced disease has the development of early‐stage To most of the adjuvant not have clinical evidence that in of HCC. the in the adjuvant has been to in advanced not in for the adjuvant treatment of HCC in of HCC with or is associated with of as as is a for adjuvant systemic The evidence is in which uses the from a systematic by on adjuvant treatment for HCC after The systematic by identified that adjuvant therapy can and in patients with liver the of are in clinical of adjuvant and therapy were in the systematic and to or The of has been in and has been to in advanced which in the adjuvant is a for the development of for treatment of HCC in the advanced setting and in the adjuvant In addition, the of by therapies on the of HCC is and the of therapy in the adjuvant setting is may warrant the of an associated in HCC for patients with who are on HCC Recommendation The AASLD with imaging over treatment for patients with cirrhosis awaiting liver transplantation who HCC. of of This is intended for patients who are on the liver transplantation with an for transplantation in to is based on current in the United policy may this The of with imaging treatment on including of of the of liver and The to of or transarterial treatment to patients with cirrhosis who have a HCC nodule and (T1) and are for liver transplantation is in on an of the liver and to undergo the and In the United current liver policy patients with HCC a or or not for with a is treated with may not the for of a HCC may be of to patients who are and have no other for as may be to the will for HCC and will This is the by the by which is If the has other for other than the of HCC, are not by the current such as or the to with If is a key is the that the may to beyond criteria and/or the This is the in the by which is The are in including the of a systematic of that adults with cirrhosis awaiting liver transplantation and treated with bridging or therapies were no were and of address the of for patients with HCC who were or were not treated with The by is a of patients with HCC for liver transplantation a United States who were not treated with The was with in Child‐Pugh class A and Child‐Pugh class The was and the patients from to a of patients within other patients from to beyond a of from and additional patients of The of was within within and within and the of tumor was estimated to be for and The authors that for patients with HCC for liver transplantation is an based on of the patients who than for patients with HCC with or with is important to that this was in an with and the may not be to with The by on for patients in with and HCC who were for transplantation who were treated with were treated with a of including or and treated with the lowest of patients with HCC a of for tumor beyond this of patients treated with a of patients in the and were of than the transplantation which may the of the In addition, the of the by was to a the than to the of on patients with or HCC. from of patients with HCC be to a understanding of In addition, of such as inform decisions of HCC with to a Should HCC Liver Transplantation or The AASLD bridging to in patients for liver transplantation within criteria to of disease and from the of of The AASLD not of therapy over for the of bridging to liver transplantation for patients within of of is as the of as or a of of such as and tumor death and tumor beyond the Milan The of hepatic to be patients for bridging in the United States with HCC within Milan criteria have been to liver transplantation by of patients with HCC have to have to liver to the policy to with have the of and in the of with current that is the for liver transplantation for HCC may based on and to and The with additional for HCC is not The of bridging therapy is to the of HCC while awaiting liver with with the Milan have been additional HCC of an with a for HCC beyond the Milan criteria while awaiting transplantation to and tumor within or while for transplantation is the to have that the is as as and and This the of the of bridging therapy for patients with HCC awaiting The are in including the of a systematic of that adults with cirrhosis awaiting liver transplantation and treated with bridging or therapies were that the of were no The of HCC and of and after liver the patients Milan patients within and the Milan and not The of the evidence was of with of and The were and the of in the United States to for the This not the various was a of and from in patients who received bridging and the not and were not the the of and for regarding which patients were to were to be by transarterial or The of was in patients treated with and alone with a and was to with in this bridging therapy is of for the patients to as as the with the and the of for the with the of have been associated with of of and and after liver transplantation has been to be in patients with HCC who received with who not the The to patients with HCC to transplantation is upon with being for based on the of hepatic An bridging not bridging for patients with HCC is to be primarily to including within the United States for in patients with HCC. to based on may to the from The of may HCC with to and to Should and HCC Milan (T3) to Milan Recommendation The AASLD that patients beyond the Milan criteria (T3) be for liver transplantation after the Milan of of The of therapy for the of be based on the in the United may be by to the board for patients with HCC after to within or may with a this is not a practice that is HCC policy may be in the to to for down‐staged patients than is no to of and for liver as a in tumor to within Milan criteria based on as a of tumor by to which is not in and of is as a in tumor to most the Milan the of may the Milan criteria to be the and support to to patients within the United patients who criteria who can be successfully down‐staged to within the Milan criteria may for HCC after by with is This is of in tumor of of as as to and of a which to therapy is have the of tumor in to tumor and to criteria for This key to patients with HCC beyond Milan criteria undergo liver transplantation after to within Milan The are in including the of a systematic of that adults with cirrhosis awaiting liver transplantation and treated with bridging or therapies were a of for associated with and were no of of with no liver the were as in were no for transplantation of with and The in the were to transplantation and and and of patients with no therapy liver transplantation was associated with and The with an of to no provided the United States which patients transplantation and and In this patients a in the patients or transplantation and in were of patients who were successfully down‐staged from to within the of in was the that were down‐staged with the patients in the most of were the of for patients to be beyond treated with with within who were not treated with no in The was from Asia and of liver with of A of patients were successfully down‐staged to the Milan criteria and were with patients who within Milan criteria and A of patients resection for was a for and the down‐staged patients being a more advanced not The of the that were the that with the lowest to be in that the was These are to has been patients with HCC within Milan The of that various transarterial and were with a of for The highest was in treated with and the lowest was in that were treated with A of a beyond the of may patients who are not liver candidates for other advanced or and the of may be by the of candidates in is in the which after as as the and transplantation are key for of transplantation can be the that can are and have criteria that be in including such as and tumor such as Liver Cancer treatment and such as and Should and HCC (T2 or T3, not for or Transplantation or The AASLD over no treatment in adults with cirrhosis and HCC (T2 or T3, no vascular involvement) who are not candidates for resection or of of The AASLD not of over of of The evidence is for Child‐Pugh class A and Child‐Pugh class B. are no to support the of for

PURPOSE: To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve the accuracy of HER2 testing and its utility as a predictive marker in invasive breast cancer. METHODS: ASCO/CAP convened an Update Committee that included coauthors of the 2007 guideline to conduct a systematic literature review and update recommendations for optimal HER2 testing. RESULTS: The Update Committee identified criteria and areas requiring clarification to improve the accuracy of HER2 testing by immunohistochemistry (IHC) or in situ hybridization (ISH). The guideline was reviewed and approved by both organizations. RECOMMENDATIONS: The Update Committee recommends that HER2 status (HER2 negative or positive) be determined in all patients with invasive (early stage or recurrence) breast cancer on the basis of one or more HER2 test results (negative, equivocal, or positive). Testing criteria define HER2-positive status when (on observing within an area of tumor that amounts to > 10% of contiguous and homogeneous tumor cells) there is evidence of protein overexpression (IHC) or gene amplification (HER2 copy number or HER2/CEP17 ratio by ISH based on counting at least 20 cells within the area). If results are equivocal (revised criteria), reflex testing should be performed using an alternative assay (IHC or ISH). Repeat testing should be considered if results seem discordant with other histopathologic findings. Laboratories should demonstrate high concordance with a validated HER2 test on a sufficiently large and representative set of specimens. Testing must be performed in a laboratory accredited by CAP or another accrediting entity. The Update Committee urges providers and health systems to cooperate to ensure the highest quality testing. This guideline was developed through a collaboration between the American Society of Clinical Oncology and the College of American Pathologists and has been published jointly by invitation and consent in both Journal of Clinical Oncology and the Archives of Pathology & Laboratory Medicine.

Abstract Somatic mutations in cancer genomes are caused by multiple mutational processes, each of which generates a characteristic mutational signature 1 . Here, as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium 2 of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA), we characterized mutational signatures using 84,729,690 somatic mutations from 4,645 whole-genome and 19,184 exome sequences that encompass most types of cancer. We identified 49 single-base-substitution, 11 doublet-base-substitution, 4 clustered-base-substitution and 17 small insertion-and-deletion signatures. The substantial size of our dataset, compared with previous analyses 3–15 , enabled the discovery of new signatures, the separation of overlapping signatures and the decomposition of signatures into components that may represent associated—but distinct—DNA damage, repair and/or replication mechanisms. By estimating the contribution of each signature to the mutational catalogues of individual cancer genomes, we revealed associations of signatures to exogenous or endogenous exposures, as well as to defective DNA-maintenance processes. However, many signatures are of unknown cause. This analysis provides a systematic perspective on the repertoire of mutational processes that contribute to the development of human cancer.

BACKGROUND: The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma. METHODS: We administered lambrolizumab intravenously at a dose of 10 mg per kilogram of body weight every 2 or 3 weeks or 2 mg per kilogram every 3 weeks in patients with advanced melanoma, both those who had received prior treatment with the immune checkpoint inhibitor ipilimumab and those who had not. Tumor responses were assessed every 12 weeks. RESULTS: A total of 135 patients with advanced melanoma were treated. Common adverse events attributed to treatment were fatigue, rash, pruritus, and diarrhea; most of the adverse events were low grade. The confirmed response rate across all dose cohorts, evaluated by central radiologic review according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was 38% (95% confidence interval [CI], 25 to 44), with the highest confirmed response rate observed in the cohort that received 10 mg per kilogram every 2 weeks (52%; 95% CI, 38 to 66). The response rate did not differ significantly between patients who had received prior ipilimumab treatment and those who had not (confirmed response rate, 38% [95% CI, 23 to 55] and 37% [95% CI, 26 to 49], respectively). Responses were durable in the majority of patients (median follow-up, 11 months among patients who had a response); 81% of the patients who had a response (42 of 52) were still receiving treatment at the time of analysis in March 2013. The overall median progression-free survival among the 135 patients was longer than 7 months. CONCLUSIONS: In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects. (Funded by Merck Sharp and Dohme; ClinicalTrials.gov number, NCT01295827.).

Multiple sclerosis (MS) is a disease with profound heterogeneity in clinical course, neuroradiological appearance of the lesions, involvement of susceptibility gene loci, and response to therapy. These features are supported by experimental evidence, which demonstrates that fundamentally different processes, such as autoimmunity or virus infection, may induce MS-like inflammatory demyelinating plaques and suggest that MS may be a disease with heterogeneous pathogenetic mechanisms. From a large pathology sample of MS, collected in three international centers, we selected 51 biopsies and 32 autopsies that contained actively demyelinating lesions defined by stringent criteria. The pathology of the lesions was analyzed using a broad spectrum of immunological and neurobiological markers. Four fundamentally different patterns of demyelination were found, defined on the basis of myelin protein loss, the geography and extension of plaques, the patterns of oligodendrocyte destruction, and the immunopathological evidence of complement activation. Two patterns (I and II) showed close similarities to T-cell-mediated or T-cell plus antibody-mediated autoimmune encephalomyelitis, respectively. The other patterns (III and IV) were highly suggestive of a primary oligodendrocyte dystrophy, reminiscent of virus- or toxin-induced demyelination rather than autoimmunity. At a given time point of the disease--as reflected in autopsy cases--the patterns of demyelination were heterogeneous between patients, but were homogenous within multiple active lesions from the same patient. This pathogenetic heterogeneity of plaques from different MS patients may have fundamental implications for the diagnosis and therapy of this disease.

Abstract Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale 1–3 . Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4–5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter 4 ; identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation 5,6 ; analyses timings and patterns of tumour evolution 7 ; describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity 8,9 ; and evaluates a range of more-specialized features of cancer genomes 8,10–18 .

BACKGROUND: In an open-label, randomized, phase 3 trial, we compared the efficacy and safety of paclitaxel with that of paclitaxel plus bevacizumab, a monoclonal antibody against vascular endothelial growth factor, as initial treatment for metastatic breast cancer. METHODS: We randomly assigned patients to receive 90 mg of paclitaxel per square meter of body-surface area on days 1, 8, and 15 every 4 weeks, either alone or with 10 mg of bevacizumab per kilogram of body weight on days 1 and 15. The primary end point was progression-free survival; overall survival was a secondary end point. RESULTS: From December 2001 through May 2004, a total of 722 patients were enrolled. Paclitaxel plus bevacizumab significantly prolonged progression-free survival as compared with paclitaxel alone (median, 11.8 vs. 5.9 months; hazard ratio for progression, 0.60; P<0.001) and increased the objective response rate (36.9% vs. 21.2%, P<0.001). The overall survival rate, however, was similar in the two groups (median, 26.7 vs. 25.2 months; hazard ratio, 0.88; P=0.16). Grade 3 or 4 hypertension (14.8% vs. 0.0%, P<0.001), proteinuria (3.6% vs. 0.0%, P<0.001), headache (2.2% vs. 0.0%, P=0.008), and cerebrovascular ischemia (1.9% vs. 0.0%, P=0.02) were more frequent in patients receiving paclitaxel plus bevacizumab. Infection was more common in patients receiving paclitaxel plus bevacizumab (9.3% vs. 2.9%, P<0.001), but febrile neutropenia was uncommon (<1% overall). CONCLUSIONS: Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with paclitaxel alone. (ClinicalTrials.gov number, NCT00028990 [ClinicalTrials.gov].).

BACKGROUND: Carotid-artery stenting and carotid endarterectomy are both options for treating carotid-artery stenosis, an important cause of stroke. METHODS: We randomly assigned patients with symptomatic or asymptomatic carotid stenosis to undergo carotid-artery stenting or carotid endarterectomy. The primary composite end point was stroke, myocardial infarction, or death from any cause during the periprocedural period or any ipsilateral stroke within 4 years after randomization. RESULTS: For 2502 patients over a median follow-up period of 2.5 years, there was no significant difference in the estimated 4-year rates of the primary end point between the stenting group and the endarterectomy group (7.2% and 6.8%, respectively; hazard ratio with stenting, 1.11; 95% confidence interval, 0.81 to 1.51; P=0.51). There was no differential treatment effect with regard to the primary end point according to symptomatic status (P=0.84) or sex (P=0.34). The 4-year rate of stroke or death was 6.4% with stenting and 4.7% with endarterectomy (hazard ratio, 1.50; P=0.03); the rates among symptomatic patients were 8.0% and 6.4% (hazard ratio, 1.37; P=0.14), and the rates among asymptomatic patients were 4.5% and 2.7% (hazard ratio, 1.86; P=0.07), respectively. Periprocedural rates of individual components of the end points differed between the stenting group and the endarterectomy group: for death (0.7% vs. 0.3%, P=0.18), for stroke (4.1% vs. 2.3%, P=0.01), and for myocardial infarction (1.1% vs. 2.3%, P=0.03). After this period, the incidences of ipsilateral stroke with stenting and with endarterectomy were similarly low (2.0% and 2.4%, respectively; P=0.85). CONCLUSIONS: Among patients with symptomatic or asymptomatic carotid stenosis, the risk of the composite primary outcome of stroke, myocardial infarction, or death did not differ significantly in the group undergoing carotid-artery stenting and the group undergoing carotid endarterectomy. During the periprocedural period, there was a higher risk of stroke with stenting and a higher risk of myocardial infarction with endarterectomy. (ClinicalTrials.gov number, NCT00004732.)